Published in Clin Infect Dis on August 22, 2006
Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data. Lancet Infect Dis (2012) 2.74
Meningococcal genetic variation mechanisms viewed through comparative analysis of serogroup C strain FAM18. PLoS Genet (2006) 2.47
Emergence of epidemic Neisseria meningitidis serogroup X meningitis in Togo and Burkina Faso. PLoS One (2011) 1.35
A generic mechanism in Neisseria meningitidis for enhanced resistance against bactericidal antibodies. J Exp Med (2008) 1.30
Sequential outbreaks due to a new strain of Neisseria meningitidis serogroup C in northern Nigeria, 2013-14. PLoS Curr (2014) 1.27
Neisseria meningitidis serogroup W, Burkina Faso, 2012. Emerg Infect Dis (2014) 1.22
Molecular characteristics and epidemiology of meningococcal carriage, Burkina Faso, 2003. Emerg Infect Dis (2007) 1.21
Neisseria meningitidis: biology, microbiology, and epidemiology. Methods Mol Biol (2012) 1.20
African meningitis belt pneumococcal disease epidemiology indicates a need for an effective serotype 1 containing vaccine, including for older children and adults. BMC Infect Dis (2010) 1.12
Study of a localized meningococcal meningitis epidemic in Burkina Faso: incidence, carriage, and immunity. J Infect Dis (2011) 1.11
Serogroup W135 meningococcal meningitis, Northern Cameroon, 2007-2008. Emerg Infect Dis (2009) 1.03
Mechanisms in Neisseria meningitidis for resistance against complement-mediated killing. Vaccine (2008) 1.01
Persistent low carriage of serogroup A Neisseria meningitidis two years after mass vaccination with the meningococcal conjugate vaccine, MenAfriVac. BMC Infect Dis (2014) 0.92
Conjugate Meningococcal Vaccines Development: GSK Biologicals Experience. Adv Prev Med (2011) 0.88
Mobile microbiological laboratory support for evaluation of a meningitis epidemic in Northern Benin. PLoS One (2013) 0.85
The Evolution of the Meningitis Vaccine Project. Clin Infect Dis (2015) 0.82
Whole-Genome Characterization of Epidemic Neisseria meningitidis Serogroup C and Resurgence of Serogroup W, Niger, 2015. Emerg Infect Dis (2016) 0.79
Epidemiology, molecular characterization and antibiotic resistance of Neisseria meningitidis from patients ≤15 years in Manhiça, rural Mozambique. PLoS One (2011) 0.77
Epidemiologic pattern of meningococcal meningitis in northern Cameroon in 2007-2010: contribution of PCR-enhanced surveillance. Pathog Glob Health (2013) 0.76
Technical Development of a New Meningococcal Conjugate Vaccine. Clin Infect Dis (2015) 0.76
Travel-related Neisseria meningitidis serogroup W135 infection, France. Emerg Infect Dis (2013) 0.75
The Establishment and Diversification of Epidemic-Associated Serogroup W Meningococcus in the African Meningitis Belt, 1994 to 2012. mSphere (2016) 0.75
Emergence and control of epidemic meningococcal meningitis in sub-Saharan Africa. Pathog Glob Health (2017) 0.75
Is the Emergence of the N. meningitidis Serogroup W ST-11 Hajj Outbreak Unraveling in the New Era of WGS? EBioMedicine (2015) 0.75
Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet (2010) 13.86
Nod1 detects a unique muropeptide from gram-negative bacterial peptidoglycan. Science (2003) 7.49
Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet (2011) 5.43
Global and regional burden of hospital admissions for severe acute lower respiratory infections in young children in 2010: a systematic analysis. Lancet (2013) 3.98
Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis (2013) 2.95
Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol (2003) 2.91
Outbreak of W135 meningococcal disease in 2000: not emergence of a new W135 strain but clonal expansion within the electophoretic type-37 complex. J Infect Dis (2002) 2.88
Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. N Engl J Med (2011) 2.72
Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clin Infect Dis (2007) 2.70
Epidemiological and molecular characteristics of a highly lethal pneumococcal meningitis epidemic in Burkina Faso. Clin Infect Dis (2006) 2.70
Bacterial meningitis in Burkina Faso: surveillance using field-based polymerase chain reaction testing. Clin Infect Dis (2004) 2.56
Revaccination with measles, tetanus, poliovirus, Haemophilus influenzae type B, meningococcus C, and pneumococcus vaccines in children after hematopoietic stem cell transplantation. Clin Infect Dis (2007) 2.45
Global network reorganization during dynamic adaptations of Bacillus subtilis metabolism. Science (2012) 2.38
Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis (2010) 2.24
Field acceptability and effectiveness of the routine utilization of zidovudine to reduce mother-to-child transmission of HIV-1 in West Africa. AIDS (2002) 2.18
Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol (2010) 2.11
Complete genome sequence of the fish pathogen Flavobacterium psychrophilum. Nat Biotechnol (2007) 2.06
Advances in the development of vaccines against Neisseria meningitidis. N Engl J Med (2010) 1.99
Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis (2009) 1.92
Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults. Vaccine (2007) 1.85
Action for child survival: elimination of Haemophilus influenzae type b meningitis in Uganda. Bull World Health Organ (2008) 1.84
Neisseria meningitidis serogroups W135 and A were equally prevalent among meningitis cases occurring at the end of the 2001 epidemics in Burkina Faso and Niger. J Clin Microbiol (2002) 1.81
Meningococcal C conjugate vaccine: the experience in England and Wales. Vaccine (2009) 1.79
Development and validation of a nonaplex assay for the simultaneous quantitation of antibodies to nine Streptococcus pneumoniae serotypes. J Immunol Methods (2004) 1.74
Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Dis J (2010) 1.73
Effectiveness of Haemophilus influenzae type B conjugate vaccine on prevention of pneumonia and meningitis in Bangladeshi children: a case-control study. Pediatr Infect Dis J (2007) 1.70
Clinical features and outcome of pediatric Neisseria meningitidis serogroup W135 infection: a report of 5 cases. Clin Infect Dis (2004) 1.69
Invasive pneumococcal disease, comorbidities, and polysaccharide vaccine use in children aged 5-15 years in England and Wales. Clin Infect Dis (2013) 1.66
Endemic foodborne botulism among Alaska Native persons--Alaska, 1947-2007. Clin Infect Dis (2011) 1.66
Seroprevalence of meningococcal serogroup C bactericidal antibody in England and Wales in the pre-vaccination era. Vaccine (2003) 1.60
Development and evaluation of a tetraplex flow cytometric assay for quantitation of serum antibodies to Neisseria meningitidis serogroups A, C, Y, and W-135. Clin Diagn Lab Immunol (2004) 1.59
Added value of PCR-testing for confirmation of invasive meningococcal disease in England. J Infect (2013) 1.58
From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak. Lancet Infect Dis (2011) 1.58
Prediction of surface exposed proteins in Streptococcus pyogenes, with a potential application to other Gram-positive bacteria. Proteomics (2009) 1.58
Down-regulation of pili and capsule of Neisseria meningitidis upon contact with epithelial cells is mediated by CrgA regulatory protein. Mol Microbiol (2002) 1.57
Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers. Pediatr Infect Dis J (2006) 1.57
Interlaboratory comparison of PCR-based identification and genogrouping of Neisseria meningitidis. J Clin Microbiol (2005) 1.56
Invasive meningococcal disease in England and Wales: implications for the introduction of new vaccines. Vaccine (2012) 1.54
Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. J Infect Dis (2006) 1.52
Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: the Global Burden of Disease Study 2015. Lancet HIV (2016) 1.51
Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage. Vaccine (2013) 1.49
Case fatality proportions and predictive factors for mortality among children hospitalized with severe pneumonia in a rural developing country setting. J Trop Pediatr (2003) 1.48
Effect of vaccination with carrier protein on response to meningococcal C conjugate vaccines and value of different immunoassays as predictors of protection. Infect Immun (2002) 1.46
Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine (2009) 1.44
A prospective study of etiology of childhood acute bacterial meningitis, Turkey. Emerg Infect Dis (2008) 1.44
Recent increase in meningitis Caused by Neisseria meningitidis serogroups A and W135, Yaoundé, Cameroon. Emerg Infect Dis (2002) 1.42
A hypothetical explanatory model for meningococcal meningitis in the African meningitis belt. Int J Infect Dis (2009) 1.41
The role of particular strains of Neisseria meningitidis in meningococcal arthritis, pericarditis, and pneumonia. Clin Infect Dis (2003) 1.41
Continuing diversification of Neisseria meningitidis W135 as a primary cause of meningococcal disease after emergence of the serogroup in 2000. J Clin Microbiol (2004) 1.40
Antibody persistence in Australian adolescents following meningococcal C conjugate vaccination. Pediatr Infect Dis J (2015) 1.38
Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine. Clin Vaccine Immunol (2010) 1.36
Three essential ribonucleases-RNase Y, J1, and III-control the abundance of a majority of Bacillus subtilis mRNAs. PLoS Genet (2012) 1.35
Emergence of epidemic Neisseria meningitidis serogroup X meningitis in Togo and Burkina Faso. PLoS One (2011) 1.35
Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines. Expert Rev Vaccines (2011) 1.35
A genome-wide survey of short coding sequences in streptococci. Microbiology (2007) 1.34
Incidence, seasonality, age distribution, and mortality of pneumococcal meningitis in Burkina Faso and Togo. Clin Infect Dis (2009) 1.34
Neisseria meningitidis serogroups A and W-135: carriage and immunity in Burkina Faso, 2003. J Infect Dis (2006) 1.34
Natural and vaccine-induced immunity and immunologic memory to Neisseria meningitidis serogroup C in young adults. J Infect Dis (2002) 1.33
Characterization of fHbp, nhba (gna2132), nadA, porA, sequence type (ST), and genomic presence of IS1301 in group B meningococcal ST269 clonal complex isolates from England and Wales. J Clin Microbiol (2009) 1.32
The impact of routine infant immunization with Haemophilus influenzae type b conjugate vaccine in Malawi, a country with high human immunodeficiency virus prevalence. Vaccine (2006) 1.30
Priorities for research on meningococcal disease and the impact of serogroup A vaccination in the African meningitis belt. Vaccine (2012) 1.30
Revaccination of children after completion of standard chemotherapy for acute leukemia. Clin Infect Dis (2007) 1.30
A generic mechanism in Neisseria meningitidis for enhanced resistance against bactericidal antibodies. J Exp Med (2008) 1.30
Transgenic mice expressing human transferrin as a model for meningococcal infection. Infect Immun (2007) 1.28
The duality of virulence and transmissibility in Neisseria meningitidis. Trends Microbiol (2002) 1.28
Evaluation and selection of tandem repeat loci for Streptococcus pneumoniae MLVA strain typing. BMC Microbiol (2005) 1.27
Increase in Neisseria meningitidis serogroup W135, Niger, 2010. Emerg Infect Dis (2010) 1.27
Epidemiological changes in meningococcal meningitis in Niger from 2008 to 2011 and the impact of vaccination. BMC Infect Dis (2013) 1.27
Antimicrobial peptides from hylid and ranin frogs originated from a 150-million-year-old ancestral precursor with a conserved signal peptide but a hypermutable antimicrobial domain. Eur J Biochem (2003) 1.25
Correlations between carbon metabolism and virulence in bacteria. Contrib Microbiol (2009) 1.25
Correlation between alterations of the penicillin-binding protein 2 and modifications of the peptidoglycan structure in Neisseria meningitidis with reduced susceptibility to penicillin G. J Biol Chem (2003) 1.25